




The relative strengths and weaknesses of Skye Bioscience Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Skye Bioscience Inc compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 7.9% points. The greatest weakness of Skye Bioscience Inc is the variable Assets, reducing the Economic Capital Ratio by 73% points.

The company's Economic Capital Ratio, given in the ranking table, is 61%, being 153% points below the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	11,651
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	13,901
Liabilities, Non-Current	171
Other Assets	246
Other Compr. Net Income	0
Other Expenses	21,067
Other Liabilities	0
Other Net Income	-2,906
Other Revenues	0
Property and Equipment	43
Research and Development	5,819
Selling, General and Administrative Expense	7,852

Output Variable	Value in 1000 USD
Assets	11,940
Liabilities	14,072
Expenses	34,739
Revenues	0
Stockholders Equity	-2,132
Net Income	-37,645
Comprehensive Net Income	-37,645
BaseVar	31,829
ECR before LimitedLiability	-325%
Economic Capital Ratio	61%